[Form 4] Kyndryl Holdings, Inc. Insider Trading Activity
Form 4 highlights: On 08/01/2025 Acrivon Therapeutics (ACRV) Chief Financial Officer Adam D. Levy satisfied withholding taxes related to vested RSUs. The company withheld 1,164 common shares at an implied price of $1.26 per share (transaction code F). Following the tax-related disposition, Levy鈥檚 direct ownership stands at 12,151 shares.
The filing indicates a routine, non-open-market share reduction for tax purposes rather than a discretionary sale. No derivative securities were involved and no new options were granted or exercised. There is no impact on the company鈥檚 operations, earnings, or guidance disclosed in this document.
Punti salienti del Modulo 4: Il 01/08/2025 il Direttore Finanziario di Acrivon Therapeutics (ACRV), Adam D. Levy, ha soddisfatto le imposte trattenute relative a RSU maturate. La societ脿 ha trattenuto 1.164 azioni ordinarie a un prezzo implicito di 1,26 $ per azione (codice transazione F). Dopo questa operazione legata alle imposte, la propriet脿 diretta di Levy ammonta a 12.151 azioni.
La comunicazione indica una riduzione ordinaria delle azioni per scopi fiscali, non una vendita discrezionale sul mercato aperto. Non sono stati coinvolti strumenti derivati n茅 sono state concesse o esercitate nuove opzioni. Non vi 猫 alcun impatto sulle operazioni, sugli utili o sulle previsioni dell'azienda riportati in questo documento.
Aspectos destacados del Formulario 4: El 01/08/2025, el Director Financiero de Acrivon Therapeutics (ACRV), Adam D. Levy, satisfizo las retenciones fiscales relacionadas con RSU adquiridas. La compa帽铆a retuvo 1,164 acciones comunes a un precio impl铆cito de $1.26 por acci贸n (c贸digo de transacci贸n F). Tras esta disposici贸n relacionada con impuestos, la propiedad directa de Levy es de 12,151 acciones.
La presentaci贸n indica una reducci贸n rutinaria de acciones por motivos fiscales, no una venta discrecional en el mercado abierto. No se involucraron valores derivados ni se otorgaron o ejercieron nuevas opciones. No hay impacto en las operaciones, ganancias o pron贸sticos de la empresa divulgados en este documento.
Form 4 欤检殧 雮挫毄: 2025雲� 8鞗� 1鞚�, Acrivon Therapeutics(ACRV)鞚� 斓滉碃鞛毂呾瀯鞛�(Adam D. Levy)臧� 旆摑頃� RSU鞐� 雽�頃� 鞗愳矞歆曥垬靹鸽ゼ 雮╇秬頄堨姷雼堧嫟. 須岇偓電� 欤茧嫻 $1.26鞚� 鞎旍嫓鞝� 臧�瓴╈溂搿� 1,164 氤错喌欤�毳� 鞗愳矞歆曥垬(瓯半灅 旖旊摐 F)頄堨姷雼堧嫟. 靹戈笀 甏�霠� 觳橂秳 頉� Levy鞚� 歆侅爲 靻岇湢 欤检嫕鞚� 12,151欤�鞛呺媹雼�.
鞚措矆 鞁犼碃電� 鞛勳潣 毵る弰臧� 鞎勲媽 靹戈笀 氇╈爜鞚� 鞚检儊鞝侅澑 牍勱车臧� 欤检嫕 臧愳唽鞛勳潉 雮橅儉雰呺媹雼�. 韺岇儩歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌, 靸堧鞖� 鞓奠厴霃� 攵�鞐悩瓯半倶 頄夓偓霅橃 鞎婌晿鞀惦媹雼�. 鞚� 氍胳劀鞐� 瓿店皽霅� 須岇偓鞚� 鞖挫榿, 靾橃澋 霕愲姅 臧�鞚措崢鞀れ棎電� 鞓來枼鞚� 鞐嗢姷雼堧嫟.
Points cl茅s du Formulaire 4 : Le 01/08/2025, le Directeur financier d鈥橝crivon Therapeutics (ACRV), Adam D. Levy, a r茅gl茅 les retenues fiscales li茅es aux RSU acquises. La soci茅t茅 a retenu 1 164 actions ordinaires 脿 un prix implicite de 1,26 $ par action (code transaction F). Suite 脿 cette op茅ration fiscale, la d茅tention directe de Levy s鈥櫭﹍猫ve 脿 12 151 actions.
Le d茅p么t indique une r茅duction de parts de routine 脿 des fins fiscales, et non une vente discr茅tionnaire sur le march茅 ouvert. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅, et aucune nouvelle option n鈥檃 茅t茅 accord茅e ou exerc茅e. Il n鈥檡 a aucun impact sur les op茅rations, les r茅sultats ou les pr茅visions de la soci茅t茅 divulgu茅s dans ce document.
Formular 4 Highlights: Am 01.08.2025 erf眉llte Adam D. Levy, Chief Financial Officer von Acrivon Therapeutics (ACRV), die Quellensteuerverpflichtungen im Zusammenhang mit erworbenen RSUs. Das Unternehmen behielt 1.164 Stammaktien zu einem impliziten Preis von 1,26 $ pro Aktie ein (Transaktionscode F). Nach dieser steuerbedingten Transaktion betr盲gt Levys Direktbesitz 12.151 Aktien.
Die Meldung weist auf eine routinem盲脽ige, nicht marktoffene Aktienreduktion aus steuerlichen Gr眉nden hin, keine diskretion盲re Ver盲u脽erung. Es waren keine Derivate beteiligt, und es wurden keine neuen Optionen gew盲hrt oder ausge眉bt. Es gibt keine Auswirkungen auf die Gesch盲ftst盲tigkeit, Gewinne oder Prognosen des Unternehmens, die in diesem Dokument offengelegt wurden.
- Disposition was tax-related (code F), not an open-market sale, limiting negative signaling.
- Executive share count declined by 1,164 shares, slightly reducing insider ownership.
Insights
TL;DR: Routine tax withholding; immaterial share change; neutral signal.
The F-code disposition shows the CFO surrendered 1,164 shares to cover taxes on vested RSUs. Because shares were not sold into the market, it does not represent a voluntary reduction in exposure. The remaining 12,151-share stake is modest, suggesting limited direct alignment, yet the transaction value (鈮�$1.5k) is immaterial relative to ACRV鈥檚 market cap. Investors should treat this filing as housekeeping with no effect on valuation or liquidity.
TL;DR: Compliance filing; no governance red flags detected.
Management followed Section 16 reporting timelines and used share withholding鈥攁n accepted practice鈥攖o settle payroll taxes on equity compensation. There are no indications of an aggressive insider selling pattern or 10b5-1 plan usage. Given the small size and mandatory nature, the filing is governance-neutral.
Punti salienti del Modulo 4: Il 01/08/2025 il Direttore Finanziario di Acrivon Therapeutics (ACRV), Adam D. Levy, ha soddisfatto le imposte trattenute relative a RSU maturate. La societ脿 ha trattenuto 1.164 azioni ordinarie a un prezzo implicito di 1,26 $ per azione (codice transazione F). Dopo questa operazione legata alle imposte, la propriet脿 diretta di Levy ammonta a 12.151 azioni.
La comunicazione indica una riduzione ordinaria delle azioni per scopi fiscali, non una vendita discrezionale sul mercato aperto. Non sono stati coinvolti strumenti derivati n茅 sono state concesse o esercitate nuove opzioni. Non vi 猫 alcun impatto sulle operazioni, sugli utili o sulle previsioni dell'azienda riportati in questo documento.
Aspectos destacados del Formulario 4: El 01/08/2025, el Director Financiero de Acrivon Therapeutics (ACRV), Adam D. Levy, satisfizo las retenciones fiscales relacionadas con RSU adquiridas. La compa帽铆a retuvo 1,164 acciones comunes a un precio impl铆cito de $1.26 por acci贸n (c贸digo de transacci贸n F). Tras esta disposici贸n relacionada con impuestos, la propiedad directa de Levy es de 12,151 acciones.
La presentaci贸n indica una reducci贸n rutinaria de acciones por motivos fiscales, no una venta discrecional en el mercado abierto. No se involucraron valores derivados ni se otorgaron o ejercieron nuevas opciones. No hay impacto en las operaciones, ganancias o pron贸sticos de la empresa divulgados en este documento.
Form 4 欤检殧 雮挫毄: 2025雲� 8鞗� 1鞚�, Acrivon Therapeutics(ACRV)鞚� 斓滉碃鞛毂呾瀯鞛�(Adam D. Levy)臧� 旆摑頃� RSU鞐� 雽�頃� 鞗愳矞歆曥垬靹鸽ゼ 雮╇秬頄堨姷雼堧嫟. 須岇偓電� 欤茧嫻 $1.26鞚� 鞎旍嫓鞝� 臧�瓴╈溂搿� 1,164 氤错喌欤�毳� 鞗愳矞歆曥垬(瓯半灅 旖旊摐 F)頄堨姷雼堧嫟. 靹戈笀 甏�霠� 觳橂秳 頉� Levy鞚� 歆侅爲 靻岇湢 欤检嫕鞚� 12,151欤�鞛呺媹雼�.
鞚措矆 鞁犼碃電� 鞛勳潣 毵る弰臧� 鞎勲媽 靹戈笀 氇╈爜鞚� 鞚检儊鞝侅澑 牍勱车臧� 欤检嫕 臧愳唽鞛勳潉 雮橅儉雰呺媹雼�. 韺岇儩歃濌秾鞚� 韽暔霅橃 鞎婌晿鞙茧┌, 靸堧鞖� 鞓奠厴霃� 攵�鞐悩瓯半倶 頄夓偓霅橃 鞎婌晿鞀惦媹雼�. 鞚� 氍胳劀鞐� 瓿店皽霅� 須岇偓鞚� 鞖挫榿, 靾橃澋 霕愲姅 臧�鞚措崢鞀れ棎電� 鞓來枼鞚� 鞐嗢姷雼堧嫟.
Points cl茅s du Formulaire 4 : Le 01/08/2025, le Directeur financier d鈥橝crivon Therapeutics (ACRV), Adam D. Levy, a r茅gl茅 les retenues fiscales li茅es aux RSU acquises. La soci茅t茅 a retenu 1 164 actions ordinaires 脿 un prix implicite de 1,26 $ par action (code transaction F). Suite 脿 cette op茅ration fiscale, la d茅tention directe de Levy s鈥櫭﹍猫ve 脿 12 151 actions.
Le d茅p么t indique une r茅duction de parts de routine 脿 des fins fiscales, et non une vente discr茅tionnaire sur le march茅 ouvert. Aucun titre d茅riv茅 n鈥檃 茅t茅 impliqu茅, et aucune nouvelle option n鈥檃 茅t茅 accord茅e ou exerc茅e. Il n鈥檡 a aucun impact sur les op茅rations, les r茅sultats ou les pr茅visions de la soci茅t茅 divulgu茅s dans ce document.
Formular 4 Highlights: Am 01.08.2025 erf眉llte Adam D. Levy, Chief Financial Officer von Acrivon Therapeutics (ACRV), die Quellensteuerverpflichtungen im Zusammenhang mit erworbenen RSUs. Das Unternehmen behielt 1.164 Stammaktien zu einem impliziten Preis von 1,26 $ pro Aktie ein (Transaktionscode F). Nach dieser steuerbedingten Transaktion betr盲gt Levys Direktbesitz 12.151 Aktien.
Die Meldung weist auf eine routinem盲脽ige, nicht marktoffene Aktienreduktion aus steuerlichen Gr眉nden hin, keine diskretion盲re Ver盲u脽erung. Es waren keine Derivate beteiligt, und es wurden keine neuen Optionen gew盲hrt oder ausge眉bt. Es gibt keine Auswirkungen auf die Gesch盲ftst盲tigkeit, Gewinne oder Prognosen des Unternehmens, die in diesem Dokument offengelegt wurden.
FAQ
How many ACRV shares did the CFO dispose of?
What was the purpose of the share disposition?
What is the CFO鈥檚 remaining ownership in ACRV?
Did the CFO sell shares on the open market?
Were any options or other derivatives exercised?
